

Haematologica  
HAEMATOL/2018/205211  
Version 4

Long-term outcome after allogeneic hematopoietic cell transplantation  
for myelofibrosis

Marie Robin, Liesbeth C. de Wreede, Christine Wolschke, Johannes Schetelig, Dirk-Jan Eikema, Maria Teresa Van Lint, Nina Simone Knelange, Dietrich Beelen, Arne Brecht, Dietger Niederwieser, Antonin Vitek, Wolfgang Bethge, Renate Arnold, Jürgen Finke, Liisa Volin, Ibrahim Yakoub-Agha, Arnon Nagler, Xavier Poiré, Hermann Einsele, Patrice Chevallier, Ernst Holler, Per Ljungman, Stephen Robinson, Aleksandar Radujkovic, Donal McLornan, Yves Chalandon, and Nicolaus Kröger

Disclosures: DML: Novartis speaker, Jazz Pharmaceutical advisory board. YC: Novartis advisory board and travel grant. NK: research grant and Honoria from Neovii. JF: research grant, speaker Honoria and travel support with MEDAC, NEOVII, NOVARTIS, RIEMSER;

Contributions: MR, YC and NK designed the study, LDW and DJE did statistics, NSK did data management, MR, YC, NK, DML analyzed the data, MR, CW, JS, MTVL, DB, AB, DN, AV, WB, RA, JF, LV, IYA, AN, XP, HE, PC, EH, PL, ST, AR and NK provided the patients, MR wrote the paper, all co-authors had opportunity to discuss results and approved the final manuscript.